Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial

Ji Yeon Kim, Yeo Jin Park, Hyo Jin Lee, Min Young Park, Oran Kwon

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Lactobacillus gasseri BNR17 is a strain isolated from human breast milk. The objective of this randomized, double-blind, placebo-controlled, and preliminary dose-finding trial was to find the effective dose and evaluate the effect of Lb. gasseri BNR17 on irritable bowel syndrome (IBS) symptoms. A total of 55 volunteers aged over 20 years with body mass index over 23 kg/m2 were randomized to intake a placebo, low-dose (BNR-L, 2 × 108 CFU/day), intermediate-dose (BNR-M, 2 × 109 CFU/day), or high-dose BNR (BNR-H, 2 × 5 × 109 CFU/day) for four weeks. Questionnaire for IBS symptoms scores and Lb. gasseri BNR17 in feces were assessed at the beginning and end of the trial. Among IBS symptoms scores, abdominal pain score was significantly reduced in BNR-H group. Lb. gasseri BNR17 was detected in all intake groups except placebo. In the preliminary study, Lb. gasseri BNR17 was confirmed to have probiotic properties.

Original languageEnglish
Pages (from-to)853-857
Number of pages5
JournalFood Science and Biotechnology
Volume27
Issue number3
DOIs
StatePublished - 1 Jun 2018

Bibliographical note

Funding Information:
This study was supported by a Bio-Synergy Research Project (2012M3A9C4048761) of the National Research Foundation funded by the Ministry of Science, ICT and Future Planning, Republic of Korea. The authors declare that they have no conflict of interest.

Publisher Copyright:
© 2017, The Korean Society of Food Science and Technology and Springer Science+Business Media B.V., part of Springer Nature.

Keywords

  • Irritable bowel syndrome
  • Lactobacillus gasseri BNR17
  • Probiotics

Fingerprint

Dive into the research topics of 'Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial'. Together they form a unique fingerprint.

Cite this